Physician profile
Maureen E Stoffa
NPI 1164483350
$2,698.81
in general payments reported to CMS, 2019-2025
29 companies · $44.76 in 2025
The $44.76 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $523 · 2021: $579 · 2022: $465 · 2023: $347 · 2024: $70.96 · 2025: $44.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $527.16 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $411.23 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Celgene Corporation | $248.61 | 2019 | |
| Pfizer INC. | $180.76 | 2019-2023 | |
| Ucb, INC. | $178.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $132.63 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Horizon Therapeutics Plc | $131.81 | 2019-2021 | |
| Tosoh Bioscience, INC. | $112.00 | 2019 | |
| Janssen Biotech, INC. | $97.65 | 2019-2021 | |
| Lilly USA, LLC | $96.54 | 2021-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $93.07 | 2019-2022 | |
| Abbott Laboratories | $77.34 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $48.75 | 2023 | Evusheld, Flumist Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.25 | 2022 | |
| Medtronic, INC. | $42.64 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $39.51 | 2021 | |
| Allergan, INC. | $31.89 | 2019-2020 | |
| Sobi, INC | $29.26 | 2023 | |
| Aurinia Pharma U.S., INC. | $28.57 | 2021-2022 | |
| Novo Nordisk INC | $25.00 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.70 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.01 | 2020 | |
| Fidia Pharma USA INC. | $14.47 | 2022 | |
| Exact Sciences Corporation | $14.20 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $13.75 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.74 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.97 | 2019 | |
| Daiichi Sankyo INC. | $11.03 | 2019 | |
| Sanofi Pasteur INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Stoffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.